Immunotherapy drug may boost outcomes for advanced nasopharyngeal cancer patients
NCT ID NCT04910347
First seen Jan 29, 2026 · Last updated May 17, 2026 · Updated 15 times
Summary
This study tests whether the immunotherapy drug nivolumab can help people with advanced nasopharyngeal cancer who still have signs of cancer after standard chemotherapy and radiation. About 57 adults aged 19 and older will receive nivolumab infusions. The main goal is to see if this approach can keep the cancer from growing for at least 2 years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED NASOPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Yonsei University Health System, Severance Hospital
RECRUITINGSeoul, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.